Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAnatara Lifesciences Ltd

Anatara Lifesciences Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.008 AUD 0.00(0%)
Last update at 2026-11-10T23:00:00Z
Market Cap
2.53M

Momentum Score

…

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Anatara Lifesciences is an Australian life-sciences company developing non-antibiotic therapies and health products for gastrointestinal disease across human and animal markets. Long-term growth may be driven by clinical and regulatory progress, licensing or partnership deals, and rising demand for antibiotic alternatives. Investors may find the company attractive because it appears positioned to address antimicrobial resistance and niche unmet needs with potential commercial upside.

Key risks include clinical or regulatory setbacks, reliance on partnership or licensing execution, limited operating cash requiring additional financing, and small-cap liquidity and execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.32M
Revenue Per Share
0.00
Gross Profit TTM
0.04M
Debt / Equity
0.76
ROE
-149.62%
Net Debt
-0.47M
ROCE
-176.02%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -1.25M -1.95M -2.08M -2.02M -2.53M
Net income -0.93M -1.95M -1.45M -2.02M -2.54M
Selling general administrative - 1.32M 1.35M 0.89M 1.38M
Selling and marketing expenses - - 0.00M - -
Gross profit -0.00M -0.63M -0.75M - -
Reconciled depreciation - - 0.00M 0.02M 0.02M
Ebit -1.25M -1.96M -1.46M -2.02M -2.53M
Ebitda -1.25M -1.96M -1.46M -2.00M -2.50M
Depreciation and amortization 0.00M 0.00M 0.00M 0.02M 0.02M
Operating income -1.25M -1.96M -1.46M -2.02M -2.53M
Other operating expenses 1.25M 2.93M 1.46M 3.28M 3.02M
Interest expense 0.00M 0.01M - 0.00M 0.00M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - - 0.01M 0.02M 0.01M
Net interest income - - 0.01M 0.02M 0.00M
Income tax expense -0.32M -0.97M -0.63M 1.25M 0.00M
Total revenue - 0.97M 0.64M - 0.00M
Total operating expenses 1.25M 1.32M 0.71M 3.28M 3.02M
Cost of revenue 0.00M 1.60M 0.75M - -
Total other income expense net 0.00M 0.00M -0.62M 1.25M -0.00M
Net income from continuing ops - - -1.45M -2.02M -2.53M
Net income applicable to common shares - - - -2.02M -2.53M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 0.82M 1.15M 1.67M 1.42M 1.77M
Other current assets 0.01M 0.02M 0.02M 0.01M 0.02M
Total liab 0.11M 0.61M 0.31M 0.49M 0.40M
Total stockholder equity 0.71M 0.54M 1.36M 0.92M 1.36M
Other current liab 0.02M 0.03M 0.06M 0.42M 0.21M
Common stock 25.32M 24.15M 23.18M 21.37M 19.91M
Capital stock - - - 21.37M 19.91M
Retained earnings -24.78M -24.03M -22.09M -20.79M -18.98M
Other liab - - - 0.00M 0.00M
Cash 0.47M 0.10M 0.93M 0.35M 1.12M
Total current liabilities 0.11M 0.61M 0.30M 0.49M 0.36M
Current deferred revenue - - - - -0.02M
Net debt -0.47M 0.31M -0.93M -0.35M -1.05M
Short term debt - 0.41M - 0.00M 0.02M
Short long term debt total - 0.41M - - 0.07M
Other stockholder equity - - - -0.58M -0.92M
Property plant equipment - - - 0.00M 0.07M
Total current assets 0.82M 1.15M 1.67M 1.42M 1.70M
Net tangible assets - - - 0.92M 1.36M
Short term investments - - 0.05M 0.05M 0.05M
Net receivables 0.33M 1.03M 0.67M 1.00M 0.51M
Accounts payable 0.09M 0.17M 0.25M 0.08M 0.15M
Accumulated other comprehensive income 0.17M 0.42M 0.28M 0.35M 0.44M
Non currrent assets other - - 0.00M -0.00M -0.07M
Non current assets total - 0.00M 0.00M 0.00M 0.07M
Capital lease obligations - - - - 0.07M
Long term debt total - - - 0.00M 0.05M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 0.05M -0.00M -0.05M
Change to liabilities - - - 0.17M -0.03M
Total cashflows from investing activities - - 0.05M -0.00M -0.06M
Net borrowings - - - -0.02M -0.02M
Total cash from financing activities 0.71M 1.39M 1.83M 1.49M -0.02M
Change to operating activities - - - -0.01M -0.03M
Net income -0.93M -1.95M -1.45M -2.02M -2.53M
Change in cash 0.37M -0.88M 0.63M -0.77M -2.31M
Begin period cash flow 0.10M 0.98M 0.35M 1.12M 3.43M
End period cash flow 0.47M 0.10M 0.98M 0.35M 1.12M
Total cash from operating activities -0.34M -2.27M -1.25M -2.26M -2.23M
Issuance of capital stock - - 1.99M 1.70M -
Depreciation 0.00M 0.00M 0.00M 0.02M 0.02M
Other cashflows from investing activities - - 0.05M 0.00M -0.05M
Change to account receivables 0.69M -0.36M 0.33M -0.50M 0.26M
Sale purchase of stock - 1.09M -0.16M -0.19M -0.01M
Other cashflows from financing activities - -0.10M 0.05M -0.02M -0.02M
Change to netincome - - - 0.07M 0.07M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.01M
Change in working capital 0.60M -0.37M 0.34M -0.50M 0.26M
Stock based compensation - 0.09M 0.03M 0.05M 0.07M
Other non cash items -0.01M -0.03M -0.17M -0.26M 0.27M
Free cash flow -0.34M -2.27M -1.25M -2.26M -2.24M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ANR
Anatara Lifesciences Ltd		 -
-%		 0.01 - - 7.95 3.56 2.18 -1.02
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Anatara Lifesciences Ltd

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

81 Flinders Street, Adelaide, SA, Australia, 5000

61 4 3802 7172

https://anataralifesciences.com

Name Title Year Born
Dr. David Lionel Brookes FACRRM, FAICD, MBBS Exec. Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Operations Officer NA
Jane Lowe Managing Director of IR Department NA
Mr. Simon Erskine Chief Devel. Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Sec. NA
Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management Commercial Mang. NA
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS Executive Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. COO & Executive Director NA
Mr. Simon Erskine Chief Development Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…